San Diego-based Dexcom — which expects to launch the G7 soon ahead of what President and CEO Kevin Sayer said will be a year full of activity — conducted the study in adults with either type 1 or type 2 diabetes (on intensive insulin therapy or not).
The study demonstrated that G7 provides accurate glucose readings with a mean absolute relative difference (MARD) of 8.2% for adults wearing arm-placed sensors, highlighting strong accuracy regardless of diabetes type or treatment regimen. Previously shared G7 data aligns with this, as Dexcom has reported 8.2% MARD in adults and 8.1% MARD in pediatric patients.
Dexcom conducted the study over 10.5 days in 316 participants. MARD registered at 8.2% for arm-placed sensors and 9.1% for abdomen-placed sensors. No serious adverse events were observed.
Other highlights from the study, published in Diabetes Technology & Therapeutics, demonstrated that G7 users can see their glucose data in 30 minutes, compared to the previous warm-up period of two hours for the current G6 offering. The next-generation platform also offers high responsiveness to changes in blood glucose to help users prevent over-treating or under-treating highs and lows.
Additionally, the Dexcom G7 system comes in at a smaller size with fewer components and improved ease of use compared to G6, while it also demonstrates high accuracy in the hypoglycemic range across a range of ages and body mass indexes (BMIs).
“The G7 CGM provides accurate glucose readings with single-digit MARD with arm or abdomen placement in adults with diabetes,” Dexcom concluded in the study.
